WallStSmart

Edwards Lifesciences Corp (EW)vsStryker Corporation (SYK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 288% more annual revenue ($25.27B vs $6.51B). EW leads profitability with a 15.4% profit margin vs 13.2%. SYK appears more attractively valued with a PEG of 1.50. SYK earns a higher WallStSmart Score of 57/100 (C).

EW

Buy

55

out of 100

Grade: C

Growth: 4.0Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 3/9Altman Z: 4.48

SYK

Buy

57

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.0Quality: 6.5
Piotroski: 3/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWUndervalued (+69.3%)

Margin of Safety

+69.3%

Fair Value

$257.97

Current Price

$89.60

$168.37 discount

UndervaluedFair: $257.97Overvalued
SYKSignificantly Overvalued (-57.3%)

Margin of Safety

-57.3%

Fair Value

$224.01

Current Price

$335.96

$111.95 premium

UndervaluedFair: $224.01Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.4810/10

Safe zone — low bankruptcy risk

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

SYK1 strengths · Avg: 9.0/10
Market CapQuality
$118.55B9/10

Large-cap with strong market position

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.094/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

P/E RatioValuation
51.2x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-25.4%2/10

Earnings declined 25.4%

SYK3 concerns · Avg: 3.7/10
P/E RatioValuation
36.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.2x leaves little room for execution misses.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

EW profiles as a mature stock while SYK is a value play — different risk/reward profiles.

EW carries more volatility with a beta of 0.85 — expect wider price swings.

EW is growing revenue faster at 13.6% — sustainability is the question.

SYK generates stronger free cash flow (415M), providing more financial flexibility.

Bottom Line

SYK scores higher overall (57/100 vs 55/100). EW offers better value entry with a 69.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?